The clinical relevance of BAALC and ERG expression levels in pediatric AML

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F13%3A10209589" target="_blank" >RIV/00064203:_____/13:10209589 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/13:10209589

Výsledek na webu

<a href="http://dx.doi.org/10.1038/leu.2012.233" target="_blank" >http://dx.doi.org/10.1038/leu.2012.233</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/leu.2012.233" target="_blank" >10.1038/leu.2012.233</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The clinical relevance of BAALC and ERG expression levels in pediatric AML

Popis výsledku v původním jazyce

Pediatric acute myeloid leukemia (AML) is a heterogeneous disease, for which survival rates have increased up to 70% over the past years. Approximately 45% of adult AML patients and 20% of pediatric AML patients are diagnosed with cytogenetically normalAML (CN-AML), which is currently classified and treated as a homogeneous intermediate-risk group. For future stratification of pediatric CN-AML, it is important to unravel the underlying molecular aberrations. For example, single-gene mutations such as NPM1 and CEBPA double mutations appeared to predict favorable outcome, whereas WT1 mutations and the cryptic NUP98/NSD1 translocation are of poor prognostic significance. In adult AML patients, the expression levels of specific genes have been associatedwith prognosis, mainly in CN-AML. For instance, high expression levels of BAALC (brain and acute leukemia cytoplasmic; 8q22) or ERG (E26 transformation-specific-related; 21q22) genes predict a poor prognosis in most adult AML studies, con

Název v anglickém jazyce

The clinical relevance of BAALC and ERG expression levels in pediatric AML

Popis výsledku anglicky

Pediatric acute myeloid leukemia (AML) is a heterogeneous disease, for which survival rates have increased up to 70% over the past years. Approximately 45% of adult AML patients and 20% of pediatric AML patients are diagnosed with cytogenetically normalAML (CN-AML), which is currently classified and treated as a homogeneous intermediate-risk group. For future stratification of pediatric CN-AML, it is important to unravel the underlying molecular aberrations. For example, single-gene mutations such as NPM1 and CEBPA double mutations appeared to predict favorable outcome, whereas WT1 mutations and the cryptic NUP98/NSD1 translocation are of poor prognostic significance. In adult AML patients, the expression levels of specific genes have been associatedwith prognosis, mainly in CN-AML. For instance, high expression levels of BAALC (brain and acute leukemia cytoplasmic; 8q22) or ERG (E26 transformation-specific-related; 21q22) genes predict a poor prognosis in most adult AML studies, con

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia

ISSN

0887-6924

e-ISSN

—

Svazek periodika

27

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

3

Strana od-do

735-737

Kód UT WoS článku

000316587300032

EID výsledku v databázi Scopus

—